Latigo Biotherapeutics (LTGO)
Develops non-opioid NaV1.8 inhibitors for acute and chronic pain.
$20.09
vs last close−0.73 (−3.49%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Insiders | 17.39% | 10.46M shares | |
|---|---|---|---|
| 3 holders · as of Aug 17, 2026 | |||
| Strategic holders | 46.81% | 28.16M shares | |
| 4 holders · as of Aug 18, 2026 | |||
| Other | 35.80% | 21.53M shares | |
| remainder | |||
60.15M company shares as of Aug 21, 2026 · holders as of their latest filing
13F
No 13F holders on record.
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| James B. Tananbaumincl. Foresite Capital Fund VI LP, Foresite Capital Management VI, LLC +4 more | 14.50% | 9.18M | 13D | Aug 17, 2026 |
| RA Capital Management, L.P. | 8.40% | 5.30M | 13G | Aug 17, 2026 |
| Deep Track Capital, LP | 7.03% | 4.45M | 13G | Aug 13, 2026 |
| AI Biotechnology LLC | 5.00% | 3.19M | 13G | Aug 18, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 10, 2026 | Foresite Capital Management V, LLC10 percent owner | Purchase | 140,000 | $18.00 | 2,008,024 |
| Aug 10, 2026 | James B. Tananbaumdirector, 10 percent owner: | Purchase | 140,000 | $18.00 | 2,008,024 |
House and Senate disclosures
Not reported.